{"transactions":[{"id":4618375,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:13.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":826,"price":157.4462,"value":130050.5612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":8722,"source":{"system":"sec-edgar","filing":"0001909817-26-000010","document":"wk-form4_1789506190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1909817/000190981726000010/wk-form4_1789506190.xml","form_type":"4"}},{"id":4618374,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:13.000Z","date":"2026-09-11","kind":"tax_withholding","planned":true,"acquired":false,"shares":1936,"price":156.22,"value":302441.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":9548,"source":{"system":"sec-edgar","filing":"0001909817-26-000010","document":"wk-form4_1789506190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1909817/000190981726000010/wk-form4_1789506190.xml","form_type":"4"}},{"id":4618373,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:03:13.000Z","date":"2026-09-11","kind":"grant","planned":true,"acquired":true,"shares":3587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":11484,"source":{"system":"sec-edgar","filing":"0001909817-26-000010","document":"wk-form4_1789506190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909817/000190981726000010/wk-form4_1789506190.xml","form_type":"4"}},{"id":760741,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-05-28T22:08:59.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":3888,"price":156.6418,"value":609023.3184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.81 to $157.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 106 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":7799,"source":{"system":"sec-edgar","filing":"0001909817-26-000007","document":"wk-form4_1780006136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000007/wk-form4_1780006136.xml","form_type":"4"}},{"id":902330,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":5479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock ."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."}],"balance_after":5479,"derivative":{"underlying":"Common Stock","underlying_shares":5479},"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902329,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Stock Option","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":31234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":31234,"derivative":{"exercise_price":124.12,"expiration_date":"2036-02-13","underlying":"Common Stock","underlying_shares":31234},"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902328,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1811,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock ."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":1812,"derivative":{"underlying":"Common Stock","underlying_shares":1811},"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902327,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock ."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":3083,"derivative":{"underlying":"Common Stock","underlying_shares":1541},"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902326,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":false,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock ."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award."}],"balance_after":4801,"derivative":{"underlying":"Common Stock","underlying_shares":1600},"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902325,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":5378,"price":124.12,"value":667517.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":11581,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902324,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":9968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award."}],"balance_after":16959,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902323,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":978,"price":124.12,"value":121389.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":6991,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902322,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1811,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7969,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902321,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":832,"price":124.12,"value":103267.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":6158,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902320,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1541,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6990,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902319,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":864,"price":123.1,"value":106358.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":5449,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":902318,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:48:50.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":true,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6313,"source":{"system":"sec-edgar","filing":"0001909817-26-000005","document":"wk-form4_1771368527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000005/wk-form4_1771368527.xml","form_type":"4"}},{"id":922932,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restriced Stock Unit","published_at":"2026-02-03T23:22:45.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":2096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and vested as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and vested as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2096},"source":{"system":"sec-edgar","filing":"0001909817-26-000003","document":"wk-form4_1770160963.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000003/wk-form4_1770160963.xml","form_type":"4"}},{"id":922931,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:22:45.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1189,"price":136.06,"value":161775.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."}],"balance_after":4713,"source":{"system":"sec-edgar","filing":"0001909817-26-000003","document":"wk-form4_1770160963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000003/wk-form4_1770160963.xml","form_type":"4"}},{"id":922930,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:22:45.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":2096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 241 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":5902,"source":{"system":"sec-edgar","filing":"0001909817-26-000003","document":"wk-form4_1770160963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000190981726000003/wk-form4_1770160963.xml","form_type":"4"}},{"id":1268294,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":1541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, and will vest as to 1,541 shares on February 13, 2026, 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, and will vest as to 1,541 shares on February 13, 2026, 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":4624,"derivative":{"underlying":"Common Stock","underlying_shares":1541},"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268293,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":1811,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, and will vest as to 1,811 shares on February 13, 2026, and 1,812 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, and will vest as to 1,811 shares on February 13, 2026, and 1,812 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":3623,"derivative":{"underlying":"Common Stock","underlying_shares":1811},"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268292,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":6401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."}],"balance_after":6401,"derivative":{"underlying":"Common Stock","underlying_shares":6401},"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268291,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Stock Option","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":34153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":34153,"derivative":{"exercise_price":117.18,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":34153},"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268290,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":830,"price":116.6857,"value":96849.131,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.87 to $117.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":3565,"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268289,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":1541,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4395,"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268288,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":955,"price":116.7939,"value":111538.1745,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":2854,"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1268287,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:08:11.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":1811,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3809,"source":{"system":"sec-edgar","filing":"0000914475-25-000059","document":"wk-form4_1739574484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000059/wk-form4_1739574484.xml","form_type":"4"}},{"id":1272425,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T23:46:24.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":false,"shares":1329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,328 shares on February 8, 2022, vested as to 1,328 shares on February 8, 2023, vested as to 1,329 shares on February 8, 2024, and vested as to 1,329 shares on February 8, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 8, 2021.  In accordance with the terms of the RSU, the award vested as to 1,328 shares on February 8, 2022, vested as to 1,328 shares on February 8, 2023, vested as to 1,329 shares on February 8, 2024, and vested as to 1,329 shares on February 8, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1329},"source":{"system":"sec-edgar","filing":"0000914475-25-000048","document":"wk-form4_1739403976.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000048/wk-form4_1739403976.xml","form_type":"4"}},{"id":1272424,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:46:24.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":700,"price":118.3144,"value":82820.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.08 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1998,"source":{"system":"sec-edgar","filing":"0000914475-25-000048","document":"wk-form4_1739403976.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000048/wk-form4_1739403976.xml","form_type":"4"}},{"id":1272423,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-12T23:46:24.000Z","date":"2025-02-08","kind":"exercise","planned":true,"acquired":true,"shares":1329,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2698,"source":{"system":"sec-edgar","filing":"0000914475-25-000048","document":"wk-form4_1739403976.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000048/wk-form4_1739403976.xml","form_type":"4"}},{"id":1285977,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restriced Stock Unit","published_at":"2025-02-04T22:42:53.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":2096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and will vest as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and will vest as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":2096,"derivative":{"underlying":"Common Stock","underlying_shares":2096},"source":{"system":"sec-edgar","filing":"0000914475-25-000023","document":"wk-form4_1738708967.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000023/wk-form4_1738708967.xml","form_type":"4"}},{"id":1285976,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:42:53.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":1104,"price":152.9433,"value":168849.4032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from  $151.85to $153.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1369,"source":{"system":"sec-edgar","filing":"0000914475-25-000023","document":"wk-form4_1738708967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000023/wk-form4_1738708967.xml","form_type":"4"}},{"id":1285975,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:42:53.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":2096,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2473,"source":{"system":"sec-edgar","filing":"0000914475-25-000023","document":"wk-form4_1738708967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000023/wk-form4_1738708967.xml","form_type":"4"}},{"id":1390386,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-10-07T20:33:13.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":1295,"price":113.66,"value":147189.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":377,"source":{"system":"sec-edgar","filing":"0000914475-24-000203","document":"wk-form4_1728333186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000203/wk-form4_1728333186.xml","form_type":"4"}},{"id":1405915,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-09-17T20:21:46.000Z","date":"2024-09-13","kind":"sale","planned":true,"acquired":false,"shares":3461,"price":121.8804,"value":421828.0644,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.31 to $122.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 238 shares purchased on February 29, 2024 and August 30, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":1672,"source":{"system":"sec-edgar","filing":"0000914475-24-000201","document":"wk-form4_1726604500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000201/wk-form4_1726604500.xml","form_type":"4"}},{"id":1641717,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:33:06.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":6165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":6165,"derivative":{"underlying":"Common Stock","underlying_shares":6165},"source":{"system":"sec-edgar","filing":"0000914475-24-000069","document":"wk-form4_1708036355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000069/wk-form4_1708036355.xml","form_type":"4"}},{"id":1641716,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Stock Option","published_at":"2024-02-15T22:33:06.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":30977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":30977,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":30977},"source":{"system":"sec-edgar","filing":"0000914475-24-000069","document":"wk-form4_1708036355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000069/wk-form4_1708036355.xml","form_type":"4"}},{"id":1641715,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:33:06.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":856,"price":133.0484,"value":113889.4304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":4895,"source":{"system":"sec-edgar","filing":"0000914475-24-000069","document":"wk-form4_1708036355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000069/wk-form4_1708036355.xml","form_type":"4"}},{"id":1641714,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:33:06.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":955,"price":133.0956,"value":127106.298,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 955 shares of common stock issued upon vesting of 1,811 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (856) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5751,"source":{"system":"sec-edgar","filing":"0000914475-24-000069","document":"wk-form4_1708036355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000069/wk-form4_1708036355.xml","form_type":"4"}},{"id":1654168,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:46:47.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":628,"price":136.78,"value":85897.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":4895,"source":{"system":"sec-edgar","filing":"0000914475-24-000051","document":"wk-form4_1707439596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000051/wk-form4_1707439596.xml","form_type":"4"}},{"id":1654167,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:46:47.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":700,"price":134.189,"value":93932.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5523,"source":{"system":"sec-edgar","filing":"0000914475-24-000051","document":"wk-form4_1707439596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000051/wk-form4_1707439596.xml","form_type":"4"}},{"id":1654166,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:46:47.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":216,"price":141.96,"value":30663.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":4894,"source":{"system":"sec-edgar","filing":"0000914475-24-000051","document":"wk-form4_1707439596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000051/wk-form4_1707439596.xml","form_type":"4"}},{"id":1654165,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-09T00:46:47.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":240,"price":141.96,"value":34070.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020.  Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":5110,"source":{"system":"sec-edgar","filing":"0000914475-24-000051","document":"wk-form4_1707439596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000051/wk-form4_1707439596.xml","form_type":"4"}},{"id":1662743,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:07:58.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":992,"price":140.7172,"value":139591.4624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.75 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":4894,"source":{"system":"sec-edgar","filing":"0000914475-24-000024","document":"wk-form4_1706918866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000024/wk-form4_1706918866.xml","form_type":"4"}},{"id":1662742,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:07:58.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":1104,"price":140.8729,"value":155523.6816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,104 shares of common stock issued upon vesting of 2,096 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (992) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.66 to $142.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5886,"source":{"system":"sec-edgar","filing":"0000914475-24-000024","document":"wk-form4_1706918866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000024/wk-form4_1706918866.xml","form_type":"4"}},{"id":1765870,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-10-04T21:07:13.000Z","date":"2023-10-02","kind":"sale","planned":true,"acquired":false,"shares":1437,"price":112.68,"value":161921.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,437 shares of common stock issued upon vesting of 2,732 restricted stock units on October 2, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,295) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 139 shares purchased on August 31, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":4894,"source":{"system":"sec-edgar","filing":"0001209191-23-052028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123052028/doc4.xml","form_type":"4"}},{"id":1791348,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-09-01T20:36:18.000Z","date":"2023-08-30","kind":"sale","planned":true,"acquired":false,"shares":1438,"price":108.2218,"value":155622.9484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.23 to $108.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":3460,"source":{"system":"sec-edgar","filing":"0001209191-23-047968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047968/doc4.xml","form_type":"4"}},{"id":1791347,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-09-01T20:36:18.000Z","date":"2023-08-30","kind":"sale","planned":true,"acquired":false,"shares":1295,"price":106.9,"value":138435.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":4898,"source":{"system":"sec-edgar","filing":"0001209191-23-047968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047968/doc4.xml","form_type":"4"}},{"id":1799010,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-08-24T00:01:25.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":107.4138,"value":171862.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,600 shares of common stock issued upon vesting of 3,038 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,438) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":6193,"source":{"system":"sec-edgar","filing":"0001209191-23-047132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047132/doc4.xml","form_type":"4"}},{"id":2014197,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:07:20.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":7245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":7245,"derivative":{"underlying":"Common Stock","underlying_shares":7245},"source":{"system":"sec-edgar","filing":"0001209191-23-009882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009882/doc4.xml","form_type":"4"}},{"id":2014196,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Stock Option","published_at":"2023-02-16T00:07:20.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":45027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":45027,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":45027},"source":{"system":"sec-edgar","filing":"0001209191-23-009882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009882/doc4.xml","form_type":"4"}},{"id":2026990,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:22:50.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":700,"price":104.1086,"value":72876.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":4755,"source":{"system":"sec-edgar","filing":"0001209191-23-007909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007909/doc4.xml","form_type":"4"}},{"id":2026989,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:22:50.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":11497,"price":102.421,"value":1177534.237,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the\nReporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from\namending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.93 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":4127,"source":{"system":"sec-edgar","filing":"0001209191-23-007909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007909/doc4.xml","form_type":"4"}},{"id":2026988,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:22:50.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":12801,"price":102.4127,"value":1310984.9727,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15624,"source":{"system":"sec-edgar","filing":"0001209191-23-007909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007909/doc4.xml","form_type":"4"}},{"id":2026987,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:22:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":240,"price":105.609,"value":25346.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.67 to $107.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":4127,"source":{"system":"sec-edgar","filing":"0001209191-23-007909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007909/doc4.xml","form_type":"4"}},{"id":2037151,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2023-02-02T22:04:52.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":1104,"price":109.9172,"value":121348.5888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,104 shares of common stock issued upon vesting of 2,096 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (992) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":3911,"source":{"system":"sec-edgar","filing":"0001209191-23-006263","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006263/doc4.xml","form_type":"4"}},{"id":2127652,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2022-11-02T22:28:30.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":1295,"price":114.12,"value":147785.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":2919,"source":{"system":"sec-edgar","filing":"0001209191-22-055389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122055389/doc4.xml","form_type":"4"}},{"id":2142820,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2022-10-05T23:07:07.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":1437,"price":106.59,"value":153169.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,437 shares of common stock issued upon vesting of 2,732 restricted stock units on October 3, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,295) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":4214,"source":{"system":"sec-edgar","filing":"0001209191-22-052896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122052896/doc4.xml","form_type":"4"}},{"id":2406988,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2022-02-10T01:04:08.000Z","date":"2022-02-08","kind":"sale","acquired":false,"shares":700,"price":79.6229,"value":55736.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $80.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":2919,"source":{"system":"sec-edgar","filing":"0001209191-22-008250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008250/doc4.xml","form_type":"4"}},{"id":2406987,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":43630,"kind":"person","name":"Boyer David W.","position":1,"cik":"0001909817","reported_name":"Boyer David W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2022-02-10T01:04:08.000Z","date":"2022-02-07","kind":"sale","acquired":false,"shares":240,"price":81.07,"value":19456.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":2291,"source":{"system":"sec-edgar","filing":"0001209191-22-008250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122008250/doc4.xml","form_type":"4"}}]}